HealthEquity surges on earnings beat and raised outlook By Investing.com

HealthEquity beat first-quarter adjusted EPS by $0.13 at $1.24 versus $1.11 consensus and slightly topped revenue estimates at $354.6 million. The company raised fiscal 2027 guidance to $4.66-$4.73 in adjusted EPS and $1.41-$1.42 billion in revenue, both above consensus, while adjusted EBITDA margin expanded to 46% from 42%. It also repurchased 1.5 million shares for $123 million and authorized an additional $1.0 billion for buybacks.

Analysis

This print reinforces that the business is moving from a volume story to a margin compounding story. The key second-order effect is that higher cash conversion and buyback capacity can mechanically lift EPS faster than revenue even if account growth normalizes, which should keep the stock re-rating durable as long as member asset growth remains above mid-teens. That makes the current setup less dependent on a single quarter’s beat and more on the sustainability of operating leverage.

The most important competitive implication is that larger scale custodians with weaker tech or lower cross-sell efficiency will likely feel pressure on pricing and retention, especially if HealthEquity continues to convert accounts into invested balances at this pace. The asset mix shift toward investments also improves economics by deepening fee-like revenue streams and reducing sensitivity to pure account acquisition costs. In other words, the moat is widening through embeddedness, not just growth.

The main risk is that the market may extrapolate margin expansion too far into a year where HSA cash yields and contribution patterns can normalize. If rate tailwinds fade or employers slow new-plan adoption over the next 2-3 quarters, multiple expansion could stall even if reported earnings stay ahead of estimates. A more subtle risk is capital returns: aggressive repurchases are supportive, but they can become a trap if valuation runs ahead of fundamentals and buybacks absorb cash at the wrong price.

Near term, the stock can continue to trend higher on estimate revisions, but the best risk/reward may be in buying pullbacks rather than chasing the after-hours move. Over a 6-12 month horizon, the thesis remains intact so long as the company sustains double-digit asset growth and margin expansion above the low-40s. If either of those slips, the market will likely compress the premium quickly because the bull case is now priced off compounding quality, not just earnings beat-and-raise optics.

Key Decisions for Investors

• Long HQY on a 1-3 month horizon on any post-earnings consolidation; target a continuation move if consensus EPS revisions follow the raised guide. Risk/reward is favorable as long as the stock holds above its post-print support and margin expansion remains visible.
• For investors with options access, buy HQY 3-6 month call spreads rather than outright calls to express upside from multiple expansion while limiting premium decay if the name mean-reverts after the initial gap.
• Pair trade: long HQY / short a lower-quality benefits-adjacent or administrator name with less visible operating leverage over the next 2 quarters. The relative trade favors the business with compounding assets and buybacks over a slower-growth peer likely to face multiple compression.
• Use the rally to sell some out-of-the-money covered calls only if already long and overexposed; the stock can keep grinding higher, but the implied post-earnings vol reset makes overwriting attractive for disciplined holders.
• Set a 2-quarter monitoring trigger: if HSA asset growth falls below the high-teens or adjusted EBITDA margin stops improving, reduce exposure. That would signal the market is starting to price the story as mature rather than compounding.